Fewer than one in 10 people that would benefit from weight-loss injections like Wegovy have access to them, states the World Health Organization as it releases its initial advice on the therapies.
With over a billion individuals worldwide currently classified as obese, it is urging broader and more equitable access to this class of drugs.
According to estimates, in excess of 2,000,000,000 will be obese by 2030 unless action is taken.
"Our new guidance affirms that excess weight is a lifelong illness that can be treated with thorough and lifelong care," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key hurdles to broad availability to the treatments that can aid individuals in losing considerable body mass, says the organization.
Skinny Jab Scarcity
Despite the present most favorable scenario, the manufacturing of these medications could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The advice encourages governments and firms to increase availability, via approaches like licensing agreements.
Exclusive production rights on the active ingredient – the primary ingredient of the drug Wegovy – is set to lapse in a number of countries in 2026.
The Way Obesity Injections Function
GLP-1 drugs mimick a biological compound to delay gastric emptying, reduce hunger and increase satiety so people eat less.
People commonly start to lose weight within a few weeks of commencing the regular doses.
Studies indicates users may regain a significant portion within a year of halting the drug, because their usual hunger resume.
To be carrying excess weight raises your chance for developing health problems, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity affects people in countries worldwide and was linked to millions of deaths worldwide in 2024, per the health agency.
